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There are conﬂicting data to support the practice of delaying the introduction of allergenic foods into the infant diet to prevent
allergy development. This study investigated immune response development after early oral egg antigen (Ovalbumin; OVA)
exposure in a rat pup model. Brown Norway (BN) rat pups were randomly allocated into groups: dam reared (DR), DR pups
challenged daily (days 4–13) with oral OVA (DR + OVAc), DR pups challenged intermittently (on day 4, 10, 12, and 13) with
o r a lO V A( D R+O V A i), formula-fed pups (FF), and FF pups challenged daily with oral OVA (FF + OVA). Immune parameters
assessed included OVA-speciﬁc serum IgE, IgG1, and IgA. Ileal and splenic messenger ribonucleic acid (mRNA) expression of
transforming growth factor-beta (TGF-β1), mothers against decapentaplegic (Smad) 2/4/7, and forkhead box P3 (Foxp3) were
determined. Ileum was stained for TGF-β1a n dS m a d 4 .Results. Feeding OVA daily to DR pups maintained systemic and local gut
antibody and immunoregulatory marker mRNA responses. Systemic TGF-β1w a sl o w e ri nD R+O V A i pups compared to DR and
D R+O V A c pups. Feeding OVA to FF pups resulted in signiﬁcantly greater OVA-speciﬁc IgE and IgG1, and lower IgA and TGF-β1
and Smad expression compared to DR pups. Conclusions. Early daily OVA exposure in the presence of maternal milk maintains
immune markers associated with a regulated immune response, preventing early allergic sensitization.
1.Introduction
Allergic disease arises due to a complex interaction between
genetic predisposition and environmental factors, breast or
formula feeding and patterns of early microbial exposure
[1–3]. The most common food allergies emerging in young
infants are to egg and peanut antigens. Approximately 6–8%
of children under three years of age are aﬀected, with the
incidence of these allergies increasing [4–7]. Food allergy to
milk and eggs typically disappears by age three to ﬁve, how-
ever there are data to suggest that the natural history of food
allergy may be changing and even food allergies, such as egg
and milk, which we think of as typically transient are show-
ing greater persistence into teenage and adult years [8, 9].
Antigen (allergen) stimulation of the mucosal immune
system is thought to be critical for the development of oral
tolerance. In early life, exposure to repeated doses of food
antigens may help prime the developing immune response
toward induction of oral tolerance [10]. The ability to
develop tolerance to allergens also appears to coincide with
the establishment of healthy gut colonization by commensal
bacteria [11]. Failure to develop oral tolerance is thought
to be associated with development of food-allergic disease.
However, the mechanism(s) by which the normal intestinal
immune system responds to food and its involvement in
the development of food allergy remains unresolved. Un-
derstanding the mechanisms involved would allow for the
potential to develop intervention strategies for the preven-
tion of food allergy and also therapeutic treatments for
infants who have already developed food allergy.
Oral tolerance to food antigens can be induced experi-
mentally, but optimization of the dose used for sensitization2 Clinical and Developmental Immunology
is critical [12]. For example, induction of tolerance to peanut
requiresasigniﬁcantlyhigheroraldosethanforegg.Animals
fed high doses of chicken OVA secrete more interleukin-4
(IL-4; associated with allergy) and less TGF-β (associated
with tolerance) than those fed low doses, where more TGF-β
and less IL-4 are produced [13]. There are only a few studies
in neonates assessing timing of antigen exposure in inducing
oral tolerance. In an animal model, Strobel et al. [14]h a v e
shown that oral OVA given in the ﬁrst week of life to mice
induces humoral as well as cell-mediated immunity [14]. In
contrast, recent studies associate early antigen exposure with
development of tolerance [15, 16]. More research is required
to determine the optimum intervention strategy to promote
oral tolerance.
Maternal milk cytokines, such as TGF-β2 and interleukin
(IL-10) have the potential to regulate immune responses to
food antigens and promote tolerance [17–23]. Although the
relationship between breastfeeding and allergy prevention
is controversial [24–26], there has recently been a growing
interest in the role of breast milk in regulating immune
response development to food antigens as new foods are
introduced into the diet [16, 27].
During infancy, T helper 1 (Th1) immune response de-
velopment is important in preventing persistent T helper 2
(Th2) responses and the subsequent promotion of allergic
disease [3]. The maturation of na¨ ıve T cells into committed
eﬀector and regulator cells depends on complex interactions
between antigen, immune cells, and the immediate cytokine
environment. TGF-β, which predominantly signals through
the Smad family of proteins, plays a major role in the
development of T-cell lineage. TGF-β induces development
of Foxp3+ T regulatory cells (Tregs) to promote tolerance
[28, 29]. IL-4 together with TGF-β inhibits the generation
of Foxp3+ Tregs by promoting Th cells that secrete IL-10,
but which do not have regulatory function [30]. TGF-β
in the local gut environment plays an important role in
developmentoftheinfantimmuneresponsetofoodantigens
as they are introduced into the diet [23, 31].
The interactions between breastfeeding and the timing
of food antigen encounter are key factors which inﬂuence
food allergy development [15, 32]. Currently there is a
concern that delayed feeding until after 6 months (tradi-
tional weaning age) may program the developing immune
response toward sensitization instead of tolerance [33, 34].
In countries where delayed feeding has been recommended,
rates of food allergy have escalated, including a greater than
5-fold increase observed in food anaphylaxis in Australian
children under 4 years of age [35]. The local intestinal
environment plays an important role in regulating immune
response development during introduction of food antigens.
Since analysis of the local gut immune response during oral
antigen introduction is not ethically feasible in infants, we
assessed in an atopic rat pup model the developing immune
response after daily early oral OVA exposure (continuous),
as compared to intermittent (occasional) OVA exposure. In
this in vivo study we focused on an early weaning time point
(day 14). The developing immune response was assessed
whenOVA wasintroduced into thediet during a critical time
in early life. Formula-fed groups were included as controls,
as we have previously shown sensitization after early oral
antigen feeding in formula-fed pups [16]. Egg ovalbumin
was used as the target antigen to assess antigen-speciﬁc
responses as it is one of the most common causes of food
allergy in infants.
2.MaterialsandMethods
2.1. Animals. The BN rat has a naturally occurring genetic
predisposition toward allergy development [36–39]. BN
rats were bred and housed in the Animal Facility of the
Child, Youth and Women’s Health Services, Adelaide and
experimentation was completed with approval from the
Child, Youth and Women’s Health Services Animal Ethics
Committee.
2.2. Cannulation and Maintenance. The details of the arti-
ﬁcial rat milk (formula) composition (Wombaroo Food
Products, South Australia, Australia; Table 1 of Supple-
mentary Material available doi 10.1155/2012/396232) and
the procedure for artiﬁcial feeding have been previously
described [16, 23]. We have also previously shown that
the artiﬁcial rat milk (formula) does not contain active
TGF-β [18, 40]. Brieﬂy, at day 4 of age, rat pups in the
formula fed groups were lightly anesthetized using forthane
(Isoﬂurathane) and surgically implanted with a ﬂexible
i.g. cannula. Artiﬁcial rat milk was delivered to rat pups
through a polyethylene line connected to the cannula using a
multisyringe infusion pump (KDS220 multisyringe infusion
pump; KD Scientiﬁc). We have demonstrated that changesin
immune markers are directly attributed to the formula and
not the surgical procedure [17].
2.3.ExperimentalDesign. Ratdamswerefedastandardnon-
puriﬁed diet which does not contain OVA (Ridley Agriprod-
ucts Pty Ltd, Victoria, Australia). Rat pups from 12 BN litters
were randomly assigned to groups (n = 8/group). Each
group (including the dam reared groups) were composed of
amixofpupstakenfromlittersoriginatingfromanumberof
diﬀerent dams. A daily or an intermittent oral OVA exposure
regime was used. There was ﬁve feeding groups: dam reared
pups (DR), DR pups receiving daily oral gavage (0.1mL) of
10mg OVA/day (OVA: Sigma-Aldrich, St.Louis, Mo, USA)
from day 4–13 (DR + OVAc), DR pups receiving an initial
oral gavage of OVA at day 4 followed by subsequent gavage
with OVA on day 10, 12, and 13, (0.1mL) of 10mg OVA/day
(DR + OVAi), formula-fed pups (FF), and FF pups receiving
a daily oral gavage (0.1mL) of 10mg OVA/d (FF+OVA). Rat
pups were killed at day 14 (prior to weaning).
Blood was collected by cardiac puncture and sera stored
at −80◦C. The spleen was removed, snap-frozen in liquid
nitrogen, and stored at −80◦C. The gastrointestinal tract
was excised, and tissue from the ileum was isolated and
either weighed and snap-frozen in liquid nitrogen for later
RNA and protein analysis or ﬁxed in 4% neutral buﬀered
f o r m a l d e h y d ef o r2 4h o u ra n dt r a n s f e r r e dt o7 0 %( v / v )
ethanol for later processing.
2.4.IgE,IgG1,andIgAAnalyses. SerumOVA-speciﬁcIgEand
OVA-speciﬁc IgG1 were quantiﬁed by ELISA as previouslyClinical and Developmental Immunology 3
Table 1
Gene Forward primer Reverse primer
TGF-β1 TGCGCCTGCAGAGATTCAAGTCAA AAAGACAGCCACTCAGGCGTATCA
Smad2 TGAGCTTGAGAAAGCCATCA TGTGTCCCACTGATCTACCG
Smad4 GGCATTGGTGTAGACGACCT GGGGTTTCTTTGATGCTCTG
iSmad7 GCAGCAGTTACCCCATCTTC TGATGGAGAAACCAGGGAAC
FoxP3 CCACACCTCCTCTTCTTCCTT TGACTAGGGGCACTGTAGGC
Cyclophilin A GGTTGGATGGCAAGCATGTG TGCTGGTCTTGCCATTCCTG
described [23]b u tO V Aw a su s e df o rc o a t i n g .S e r af r o m
the pups were diluted 5-fold for analysis in the ELISA assay.
Standards and samples were added in duplicate and detected
colorimetrically using 3,3 ,5,5  tetramethylbenzidine (TMB;
Sigma-AldrichChemicalCo.,St.Louis,Mo,USA).Thelimits
of detection for the OVA-speciﬁc IgE and OVA-speciﬁc IgG1
ELISA assays were 1.95 and 0.78ng/mL, respectively. The
plates were read with a Sunrise Magellan plate reader at
450nm (Tecan Group Ltd, Mannedorf, Switzerland) and
data expressed as ng immunoglobulin/mL sera.
IgA was quantiﬁed by ELISA using ileal tissue. Ileal
protein lysates for use in the IgA ELISA were prepared as
described in Tooley et al. [16]. Brieﬂy, ileal protein lysates
were prepared by adding a cocktail of protease inhibitors
(Sigma-AldrichChemicalCo.,St.Louis,Mo,USA)tointesti-
nal tissue (1mL/100mg tissue), which was then homoge-
nized and centrifuged twice. Supernatants were collected,
aliquoted, and stored at −80◦C until analysed. Samples from
pups for IgA analyses were diluted 1/2000 for DR groups and
1/5 for FF groups. The standard, puriﬁed rat IgAκ,c a p t u r e
antibody, mouse anti-rat IgA and the secondary, biotin
mouse anti-rat IgA were all purchased from BD Biosciences
(Franklin Lakes, NJ, USA). Brieﬂy, 96-well plates (Greiner,
Frickenhausen, Germany) were coated with 2μg/mL mouse
anti-rat IgA in phosphate-buﬀered saline (PBS) overnight
at 4◦C. The wells were washed ﬁve times with wash buﬀer
(PBS/0.05% Tween20) and then blocked for 1 hour at room
temperature with 1% Polypep protein digest (Sigma-Aldrich
Chemical Co., St. Louis, Mo, USA) in PBS. The samples and
standards (puriﬁed rat IgA; standard range: 125ng/mL to
1.95ng/mL)werethenaddedtotheplateandincubatedfor1
hour at room temperature. After incubation, the plates were
washed ﬁve times and biotin mouse anti-Rat IgA was added
(0.5μg/mL). Plates were incubated at room temperature
for 1 hour and then washed six times. Following the ﬁnal
wash, a solution of ABC reagent (Vector Laboratories, Inc.
Burlingame, Calif, USA) was added and the plates incubated
for30minutesatroomtemperature.Plateswerethenwashed
sixtimes;afterwashingTMBsubstratewasaddedtothewells
for 30 minutes after which time the reaction was stopped
using 50 μLo f2NH C la n dr e a da ta na b s o r b a n c eo f4 5 0n m .
The limit of detection for the IgA was 1.95ng/mL. Data was
expressed as ng immunoglobulin/g of tissue.
2.5. Real-Time PCR. RNA extraction from the spleen and
ileum, cDNA synthesis, primer design, real-time PCR,
and analysis were performed as previously described [16].
Primers for TGF-β1, Smad2, Smad4, iSmad7, and Foxp3 are
provided in Table 1.
2.6. Histological Assessment. Immunohistochemical analyses
of TGF-β1a n dS m a d 4w e r ec a r r i e do u to ns e g m e n t so ft h e
ileum. Four-micrometer sections were cut from paraﬃn-
embedded tissue and placed on gelatin-coated slides. Sec-
tions were deparaﬃnized with xylene and rehydrated in
graded ethanol in water. Sections were then placed in 10mM
citratebuﬀer(1.8mMcitric acid; 8.2mMsodiumcitrate,pH
6.0) and subjected to heat-induced epitope recovery using
microwave irradiation [41]. Sections were then cooled at
room temperature for 30 minutes before staining.
ForTGF-β1,sectionswerestainedasdescribedinPenttila
et al. [40]. For Smad4 staining, tissue sections were ﬁrst
incubated with 5% normal horse serum/1% bovine serum
albumin (5% NHS/1% BSA) in Tris buﬀered saline (TBS)
for 30 minutes at room temperature to block nonspeciﬁc
binding of the secondary antibody. The blocking antibody
was then decanted and 100μL of anti-Smad4 IgG (8μg/mL;
Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA) was
added, and the sections were incubated overnight at 4◦C.
After incubation the sections were then washed three times
in TBS containing 0.05% Tween 20 (TTBS; 5 minutes/wash)
and then incubated in 3% (v/v) hydrogen peroxide for 15
minutes at room temperature to quench endogenous peroxi-
dase activity. The sections were then washed three times with
TBS (5 minutes/wash) after which the secondary antibody
(HRP conjugated donkey anti-mouse—3.2μg/mL; Jackson
Immuno Research Laboratories, West Grove, PA. USA) was
applied to the sections (100 μL per section) and the sections
incubated for 60 minutes at room temperature. The sections
were then washed with TTBS (5 minutes/wash) two times
followedbytwowasheswithTBS(5minutes/wash).Forboth
TGF-β1 and Smad4 staining, immunohistochemistry reac-
tions were visualized using a 3,3-diaminobenzidine (DAB)
substrate plus enhancer (Invitrogen, Carlsbad, Calif, USA).
After substrate development, sections were counterstained,
dehydrated with graded ethanol, and mounted.
Control samples for TGF-β1 included sections incubated
with normal chicken IgY (R&D Systems Inc, Minneapolis,
MN, USA) or with antibody dilution buﬀer only. Control
samples for Smad4 included sections incubated with 5%
NHS/1% BSA (R&D Systems Inc, Minneapolis, MN, USA)
or with the isotype control, mouse IgG1 (8μg/mL). Digital
images of both TGF-β1 and Smad4 immunohistochemical
sections (400x magniﬁcation) were taken and analysed using4 Clinical and Developmental Immunology
Image Pro Plus software, version 5.1 (Media Cybernetics,
Bethesda, Md, USA).
2.7. Statistical Analyses. All data were expressed as the mean
+ standard error of the mean (SEM). Data was assessed
for Normality before analysis. OVA-speciﬁc IgE and IgG1
and TGF-β1, Foxp3, Smad2, Smad4, and iSmad7 mRNA
expression data were evaluated utilizing a nonparametric
one-way ANOVA (Kruskal-Wallis) followed by a Dunn’s
Multiple Comparisons post hoc test. Diﬀerences were con-
sidered signiﬁcant at P<0.05. All statistical analyses and
comparisons were made using GraphPad Prism software,
version 3 (GraphPad Software Inc, San Diego, Calif, USA).
3. Results
3.1. Bodyweight Change. Feeding OVA to either DR or FF
pups did not aﬀect body weight gain at day 14 (data not
shown).
3.2. OVA-Speciﬁc IgE, OVA-Speciﬁc IgG1 and IgA. OVA given
during formula feeding resulted in a signiﬁcantly increased
OVA-speciﬁcIgEtitercomparedwiththeDRandDR+OVAc
groups(P<0.05;Figure 1(a)).SerumOVA-speciﬁcIgG1was
also signiﬁcantly increased in the FF+OVA group (P<0.05)
compared with the DR, DR + OVAc,D R+O V A i, and FF
groups (Figure 1(b)). Importantly, OVA-speciﬁc IgG1 titers
did not diﬀer signiﬁcantly between the DR groups regardless
of oral OVA exposure. IgA was signiﬁcantly greater in the
DR, DR + OVAc,D R+O V A i groups (P<0.01) and barely
detectable in the FF and FF + OVA groups (Figure 1(c)). IgA
levels did not diﬀer between the DR groups.
3.3.TGF-β1andSmadmRNAExpressioninSpleenandIleum.
TGF-β1 mRNA expression in the spleen was signiﬁcantly
greater in the DR and DR+OVAc groups compared with the
DR + OVAi,F Fa n dF F + O V Ag r o u p s( P<0.05; Figure 2(a)).
SplenicTGF-β1mRNAexpressiondidnotdiﬀersigniﬁcantly
between the DR and DR + OVAc groups. TGF-β1m R N A
expression in the ileum was signiﬁcantly greater in all DR
groups regardless of OVA exposure compared with the FF
and FF + OVA groups (P<0.05; Figure 2(a)); however
there were no signiﬁcant diﬀerences in ileal TGF-β1m R N A
expression between the DR groups. Foxp3 mRNA expression
in the spleen was signiﬁcantly greater in the DR, DR +
OVAc, and FF groups compared with the DR + OVAi and
FF + OVA groups (P<0.05; Figure 2(b)). Expression did
not diﬀer signiﬁcantly between the DR, DR + OVAc,a n d
FF groups. Although the mRNA expression of Foxp3 in the
ileum did not diﬀer between the DR groups, expression was
signiﬁcantly greater in DR groups compared with the FF and
FF+OVA groups (P<0.05; Figure 2(b)).
The Smad pathway was also investigated by analyzing
the mRNA expression of Smad2, Smad4, and iSmad7 in the
spleen and ileum. In the spleen, Smad2 mRNA expression
was signiﬁcantly greater in DR group compared with the
DR + OVAi and FF + OVA groups (P<0.05; Figure 3(a)).
Expression of splenic Smad2 mRNA did not diﬀer signiﬁ-
cantly between the DR, DR + OVAc, and FF groups. Smad
4 mRNA expression in the spleen was signiﬁcantly greater in
DR and FF groups compared with the DR+OVAi group(P<
0.05; Figure 3(b)). No signiﬁcant diﬀerencein Smad4 mRNA
expressionwasobservedbetweentheDR,DR+OVAc,FF ,and
FF + OVA groups. iSmad7 mRNA expression in the spleen
was signiﬁcantly greater in the DR and DR + OVAc groups
compared with the DR + OVAi and FF + OVA groups (P<
0.05;Figure 3(c)).NosigniﬁcantdiﬀerenceiniSmad7mRNA
expression in the spleen was observed between DR, DR +
OVAc, and FF rats. In the ileum, Smad2, Smad4 and iSmad7
mRNA expression was signiﬁcantly greater in the DR groups
regardless of OVA exposure compared with FF and FF+OVA
groups (P<0.05; Figures 3(d), 3(e),a n d3(f)). There were
no signiﬁcant diﬀerences in Smad2, Smad4, and iSmad7
mRNA expression in the ileum between the DR, DR+OVAc,
and DR+OVAi groups.
3.4. TGF-β1 and Smad4 Protein Expression in the Ileum.
TGF-β1 staining was mainly localized to the enterocytes and
occasional individual cells in the villus lamina propria of the
ileum (Figures 4 (a), 4(b), 4(c), 4(d), and 4(e)). No TGF-β1
staining was evident at the base of the villus in the crypts
or the surrounding lamina propria. Staining of Smad4 was
localized throughout the enterocytes of the villi and in cells
of the lamina propria in all rat groups (Figures 4(g), 4(h),
4(i),4(j),and4(k)).Smad4wasnotdetectedingobletcellsor
the longitudinal layer of smooth muscle. TGF-β1a n dS m a d 4
staining was consistently more abundant in the DR groups
regardless of OVA exposure when compared to staining in
sections from FF or FF + OVA rats. No background staining
w a sd e t e c t e di nn e g a t i v ec o n t r o l s( F i g u r e s4(f) and 4(i)).
4. Discussion
We investigated the immune response proﬁle after early
oral OVA exposure in DR and FF rat pups. Early oral OVA
exposure in rat pups, regardless of the dosage regime, in
the presence of maternal milk maintained a similar immune
response proﬁle to that observed in DR unchallenged rats,
with low levels of circulating OVA-speciﬁc IgE; and IgG1. In
contrast to the low OVA IgG1 response seen in the rat pups
fed formula alone (no OVA challenge), the IgE response to
OVA was high (not signiﬁcantly diﬀerent from that seen
in the OVA challenged formula fed rat pups). We have
previously shown that formula feeding induces an overall
increase in total serum IgE, this increased IgE response may
contain cross-reactive antibodies to OVA [16]. Formula
fed groups were only included as controls in this study,
as we have previously shown sensitization after early oral
antigen feeding in formula-fed pups [16]. The results seen
for OVA-speciﬁc IgG1 are similar to our previous published
data relating to feeding cow’s milk allergen, β-lactoglobulin
(BLG), where we showed that sensitization was prevented
in maternal-milk-fed pups given oral BLG early in life.
Importantly we showed that this regulated immune proﬁle
persisted into postweaning age [16, 23]. In contrast, immuneClinical and Developmental Immunology 5
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Figure 1: OVA-speciﬁc IgE, OVA-speciﬁc IgG1, and ileal IgA after oral OVA commenced at day 4 in DR or FF rat pups. Bars are mean +
SEM, n = 8/group. Means without a common letter diﬀer, P<0.05.
activation and allergy development resulted when BLG was
fed in the presence of formula [16].
TGF-βs are an important family of growth factors in-
volved in maintaining homeostasis in the intestine, regulat-
ing inﬂammation and allergy development and promoting
oral tolerance development in infants [31]. TGF-β is the
predominant cytokine present in human and rodent milk
[40, 42]. TGF-β predominately signals through the Smad
protein family. Smad2 and Smad3 are phosphorylated after
activation of TGF-β receptors, forming a complex with
Smad4. Once translocated into the nucleus, this complex
then binds to the Smad binding element in the promoter
region of TGF-β target genes and regulates transcriptional
responses in conjunction with DNA-binding partners [43,
44]. By also assessing Smad genes involved in the pathway
we have been able to further elucidate the function of
TGF-β1 in the development of immune responses in the
gut when OVA was introduced. In the DR + OVAc group,
TGF-β1 mRNA expression in both the spleen and the local
gut environment did not diﬀer signiﬁcantly from that in
unchallenged DR rats. However, DR rats receiving oral
OVA intermittently displayed decreased TGF-β1a n dS m a d 2 ,
Smad4, and iSmad7mRNA expression in the spleen. Collec-
tively, we have shown that the DR+OVAi,F F ,a n dF F+O V A
groups exhibited the greatest systemic impairment of the
TGF-β1/Smad pathway with lower mRNA expression of the
TGF-β1/Smad genes. However, in the intestine, which is the
ﬁrst site of exposure to food antigens we observe a diﬀerent6 Clinical and Developmental Immunology
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Figure 2: Splenic and ileal cytokine mRNA expression in DR and FF pups at day 14 with or without daily/intermittent treatment with OVA.
TGF-β1 mRNA (a) and Foxp3 mRNA (b) as determined by real-time PCR. Bars are mean + SEM, n = 7-8. Means without a common letter
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patternofexpression.DRratsexposedtoOVAintermittently
maintained a TGF-β1/Smad mRNA expression proﬁle simi-
lar to the unchallenged DR group. One possible explanation
is that external sources of TGF-β, provided by maternal milk,
are suﬃcient to maintain the expression of these genes in the
local gut environment. Our current data also shows that in
the ileum of FF rats, with or without OVA exposure, lower
levels of all Smad mRNA’s were present when compared to
the DR groups. High levels of TGF-β are present in rat milk
during early lactation, with the highest levels detected just
after birth. TGF-β levels then decrease toward weaning. In
contrast in maternal-fed rat pups, the number of TGF-β1-
producing cells and mRNA in the intestine is low after birth,
but levels increase over the weaning period [40]. As TGF-β
is essential for maintaining homeostasis in the intestine and
promotion of T regulatory cells, our data suggests that the
local gut environment in FF pups is impaired with regard
to the potential for developing regulated immune responses
to food antigens. We have shown in previous studies that
when BN rat pups are fed a formula supplemented with
physiologicallevelsofTGF-β,markersassociatedwithallergy
development are reduced and the immune response proﬁle
to the cow’s milk allergen, BLG, is not signiﬁcantly diﬀer-
ent to that seen in unchallenged maternal-milk-fed pups.
This regulated immune response proﬁle extended out to
postweaning ages, highlighting the importance of TGF-β inClinical and Developmental Immunology 7
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Figure 3: Splenic and ileal mRNA expression of Smad pathway genes in DR and FF pups at day 14 with or without daily/intermittent
treatment with OVA. Smad2, 4, and 7mRNA levels in spleen (a, b, and c) and Smad2, 4 and 7mRNA levels in ileum (d, e, and f) as
determined by real-time PCR. Bars are mean + SEM, n = 7-8. Means without a common letter diﬀer, P<0.05.
developing and preventing sensitization to food antigens
[23].
TGF-β1 signals are controlled by inhibitory iSmads, pre-
dominantly iSmad7 [43, 44]. We have shown, particularly in
the ileum, that TGF-β1a n diSmad7mRNA levels maintain a
homeostaticbalance,possiblybyforminganegativefeedback
loop. It has been documented that the transcription of
iSmad7 can be turned on by TGF-β itself in the TGF-β/Smad
signalling pathway [45]. This suggests that even in the pres-
enceofearlyoralantigenchallengethemucosalimmune sys-
tem can develop and maintain such regulatory mechanisms.
TGF-β signaling promotes T-cell tolerance and helps
maintain normal homeostasis throughout the lifespan. TGF-
β preferentiallyincreasesIgAantibodyresponsesbydirecting
isotype switching to IgA in Peyer’s patches [46]. Ogawa et al.
[47] showed in a study of newborn infants during their ﬁrst
month of life that an increase of serum IgA correlated with
levels of both TGF-β1a n dT G F - β2 in maternal colostrum
[47]. Our data supports the role of TGF-β in regulating
IgA levels during early food introduction in the presence of
maternal milk. We have shown that early oral OVA exposure
in the presence of maternal milk, as compared to formula,
maintained IgA levels. In the FF groups, IgA levels were only
slightly above the detection limit of the assay.
As well as being involved in epithelial growth, IgA
production, DC maturation, and Treg cell diﬀerentiation,
TGF-βs inhibit inﬂammation and regulate inﬂammatory
responses in the intestine [17, 48–51]. In the adult intestine,
TGF-β1 is the predominant isotype present in epithelial
and lamina propria cells [52]. We assessed the localization
pattern of both TGF-β1 and Smad4 in the intestine of
DR and FF rats with or without antigen exposure. More
abundant staining of TGF-β1 and Smad4 was observed in
all the DR groups, regardless of antigen exposure compared
with the FF groups. The histology supports our TGF-β1
and Smad4mRNA expression data in the ileum and again
highlights the potential for sensitization in FF rat pups. We
havedemonstratedinthelocalgutenvironmentthatformula
feeding early in life results in an overall suppression of TGF-
β1 and the signaling genes involved in its pathway, namely,
Smad2, Smad4, and iSmad7.
TGF-β is also required for induction of Tregs, which
play a critical role in maintaining immune homeostasis in
the intestine. Foxp3+ (CD4+CD25+Foxp3+) regulatory cells
are necessary for the development of oral tolerance [53–
56]. Foxp3mRNA expression was maintained in the ileum
of DR rats receiving OVA daily with expression levels similar
to that seen in the ileum of unchallenged DR rats. Ileal
Foxp3mRNA expression in the DR + OVAi group did not
diﬀer from the DR or DR + OVAc groups but a decrease
in splenic Foxp3mRNA was observed in the DR + OVAi
g r o u p .Ad e c r e a s ei nF o x p 3 m R N Ae x p r e s s i o nw a sa l s o
observed in both the ileum and spleen of FF rat pups
receiving OVA. We have previously shown that this decrease8 Clinical and Developmental Immunology
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Figure 4: Mucosal immunolocalization of TGF-β1 and Smad4 in DR and FF pups at day 14 with or without daily/intermittent treatment
with OVA. Representative images are shown for all groups. Positive staining is indicated as a brown color. TGF-β1 (a–f: DR (a), DR + OVAc
(b), DR+OVAi (c), FF (d), FF+OVA (e), and negative control (f)) and Smad4 (G-L: DR (g), DR+OVAc (h), DR+OVAi (i), FF (j), FF+OVA
(k), and negative control (l)).
in FoxP3mRNA expression was also noted in the mesenteric
lymph node of FF BN rat pups at day 14, and that the
frequency of Foxp3+ cells was greater in maternal-fed BN rat
pups receiving a continuous dose of BLG [16]. The role of
Foxp3+/CD25+/CD4+ Tregs in development of food allergy
is at present unclear. It has been shown that Foxp3+cells are
present in the intestine of food allergic children, but Foxp3
transcription levels are low [57]. In contrast, other studies
reportlowerexpressionofFoxp3anddefectsintranscription
[55]. It has been shown that repeated small doses of antigens
are necessary for the development of oral tolerance mediated
by Treg cells [58]. Our results suggest that continuous as
opposed to intermittent antigen exposure in the presence
of maternal milk maybe required to promote Treg cells
and Foxp3 expression in the periphery. A daily repeated
exposuretoOVAascomparedtoanintermittent(occasional)
exposure may allow the immature immune system time
to “practice” and therefore help to prime for development
of a regulated immune response to prevent sensitization,
potentially enhancing later tolerance development.
In infants with a predisposition toward allergy develop-
ment, delaying the feeding of solids until after 6 months
may program the developing immune response toward sen-
sitization [15, 59]. Factors such as the duration of exclusive
breastfeeding, timing of introduction, and the type of other
foods (allergens) in the diet are also thought to inﬂuence the
switch between tolerance and sensitization [15]. In support
of this, in a previous time course study of early cow’s milk
allergen exposure (BLG was commenced at day 4 of life)
we showed a reduction in the levels of markers associated
with allergy development at day 10, 14, and 21 of life after
BLG exposure in the presence of maternal milk [16].In our
current study assessing an early weaning time point (day 14
of life) we show an upregulation of the levels of markers
associated with immuno-regulatory mechanisms after early
OVAexposure.DailybutnotintermittentoralOVAexposure
commenced on day 4 during maternal milk feeding created
an immune environment with the potential to decrease
sensitization to food antigens. Foxp3mRNA expression,
TGF-β1mRNAandproteinexpression,andexpressionofthe
Smad genes involved in TGF-β signaling were maintained in
both the microenvironment of the gut and the periphery.
Early regular exposure to food antigens (OVA) in the
presence of maternal milk in early life maintains immune
regulatory mechanisms preventing allergic sensitization.
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